Compare MGIC & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGIC | INM |
|---|---|---|
| Founded | 1983 | 1981 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.3M | 3.7M |
| IPO Year | 1991 | N/A |
| Metric | MGIC | INM |
|---|---|---|
| Price | $26.25 | $1.22 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | 44.7K | ★ 145.5K |
| Earning Date | 11-18-2025 | 02-11-2026 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | ★ 16.15 | N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $603,216,000.00 | $4,798,116.00 |
| Revenue This Year | $12.87 | N/A |
| Revenue Next Year | $6.23 | N/A |
| P/E Ratio | $33.24 | ★ N/A |
| Revenue Growth | ★ 12.65 | N/A |
| 52 Week Low | $11.36 | $1.13 |
| 52 Week High | $27.44 | $8.27 |
| Indicator | MGIC | INM |
|---|---|---|
| Relative Strength Index (RSI) | 58.17 | 40.93 |
| Support Level | $24.52 | $1.18 |
| Resistance Level | $27.17 | $1.35 |
| Average True Range (ATR) | 0.75 | 0.10 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 65.58 | 17.19 |
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.